Liver Cancer in the Middle East: Hepatitis C-Induced Hepatocellular Carcinoma In the Middle East

Said Al-Busafi*, Khalid Al Naamani

*Corresponding author for this work

Research output: Book/ReportBook

Abstract

Hepatocellular carcinoma (HCC) is an important health problem around the world. It represents >85% of primary liver cancers worldwide. Chronic hepatitis C (CHC) infection is one of the major etiologic factors that cause HCC by producing an inflammatory, fibrogenic, and carcinogenic tissue microenvironment in the liver. In general, HCC develops only after many years of hepatitis C virus (HCV) infection. The increased risk is limited to a great extent to patients with cirrhosis or advanced fibrosis. Given the current prevalence of HCV infection in Middle Eastern countries, the incidence and mortality rates of HCC are likely to increment throughout the following ten years. Therefore, this chapter reviews the epidemiology, pathogenesis, and risk factors of HCV and HCV-related HCC in the Middle East (ME). Besides, the preventive and treatment strategies of HCV-related HCC are discussed individually. The comprehensive understanding of opportunities and limitations for successfully implementing the World Health Organization (WHO) HCV elimination targets by 2030 in the ME will help to develop strategies and plans tailored to each country's needs in this region.
Original languageEnglish
Place of PublicationSwitzerland
PublisherSpringer Nature Switzerland AG
Number of pages38
ISBN (Electronic)978-3-030-78737-0
ISBN (Print)978-3-030-78736-3
Publication statusPublished - Oct 2021

Cite this